Oral glucose solution for the treatment of persistent asymptomatic neonatal hypoglycemia: a randomized, double-blind, placebo-controlled trial.
Ratchada Kitsommart, Thananjit Petchkum, Buranee Yangthara et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized, double-blind, placebo-controlled trial evaluated the efficacy of buccal 50% dextrose solution (D50W) in treating persistent asymptomatic hypoglycemia in at-risk late preterm and term neonates. Among 400 enrolled infants, the OG group showed a median blood glucose increment of 28.0 mg/dL compared to 22.5 mg/dL in the placebo group (p < 0.01), but the proportion requiring intravenous dextrose did not differ significantly (4.9% vs. 8.7%; p = 0.18).
Key findings
- Buccal D50W resulted in a greater median blood glucose increment of 28.0 mg/dL compared to 22.5 mg/dL in the placebo group (p < 0.01).
- The proportion of infants requiring IV dextrose was 4.9% in the OG group versus 8.7% in the placebo group (p = 0.18).
- No episodes of hyperglycemia, choking, vomiting, or mucosal irritation were observed in either group.
Why it matters
The findings suggest that while buccal D50W can effectively increase blood glucose levels in neonates with hypoglycemia, it does not significantly reduce the need for intravenous therapy. This has implications for managing neonatal hypoglycemia in resource-limited settings.